PharmaTutor

Friday, October 11, 2013

FORMULATION AND CHARACTERIZATION OF RALOXIFENE BETA-CYCLODEXTRINE INCLUSION COMPLEX FOR SOLUBILITY ENHANCEMENT

Raloxifene is a second genaration selective estrogen receptor modulator used to prevent osteoporosis in postmenopausal women. which is insoluble in water and half life is 27.7 hr. it has estrogen effect on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. raloxifene needs enhancement of solubility and dissolution rate to improve its oral bipavailability and therapeutic efficasy. among  the various approaches to enhance solubility and dissolution rate of poorly soluble drugs complexation with cyclodextrine is an effective and indutrially accepted technique. In the present  investigation complexation of raloxifene with β-CD was carried out by using various technique like physical blending method, kneading method, solvent evaporation method and co-precipitation method. From the various characterization studies like solubility determination, drug content determination, production yield & in vitro dissolution study, it was observed that there was a significant rise in the aqueous solubility and dissolution rate of the raloxifene from the β-cd incusion complex. from the result of statistical analysis, batch RLX-6 by kneading method was found to be optimised batch, because of the maximum enhancement in solubility and rate of dissolution.  Optimised batch was also studied for compatibility by FTIR studies, and also it was found to be stable for the period of 90 days as per the ICH guidelines.



No comments: